12.97
-0.01(-0.08%)
Currency In USD
| Previous Close | 12.98 |
| Open | 12.95 |
| Day High | 13.03 |
| Day Low | 12.66 |
| 52-Week High | 13.49 |
| 52-Week Low | 6.69 |
| Volume | 2.18M |
| Average Volume | 1.74M |
| Market Cap | 4.08B |
| PE | 1,297 |
| EPS | 0.01 |
| Moving Average 50 Days | 12.17 |
| Moving Average 200 Days | 9.45 |
| Change | -0.01 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $864.09 as of January 14, 2026 at a share price of $12.97. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $2,674.23 as of January 14, 2026 at a share price of $12.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
GlobeNewswire Inc.
Dec 22, 2025 9:01 PM GMT
Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
GlobeNewswire Inc.
Dec 09, 2025 9:01 PM GMT
Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) to
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
GlobeNewswire Inc.
Dec 05, 2025 1:00 PM GMT
Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each doseFindings hi